Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arvind, Chaudhry
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies	Active, not recruiting	1/2	81	Europe, US, RoW	Orelabrutinib (ICP-022)	Beijing InnoCare Pharma Tech Co., Ltd.	Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies	12/23	01/25
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors	Recruiting	1/2	80	US, RoW	HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule	Shanghai Huaota Biopharmaceutical Co., Ltd.	Advanced Solid Tumor, NSCLC	08/24	08/24